Almahamoudou Mahamar1, Djibrilla Issiaka1, Ahamadou Youssouf1, Sidi M Niambele1, Harouna M Soumare1, Oumar Attaher1, Amadou Barry1, David L Narum2, Patrick E Duffy2, Brian Greenwood3, Michal Fried2, Alassane Dicko4. 1. Mali Research & Training Center, Faculty of Medicine, Pharmacy and Dentistry, University of Science, Techniques and Technologies (USTT), Bamako, Mali. 2. Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Rockville, MD, USA. 3. London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, UK. 4. Mali Research & Training Center, Faculty of Medicine, Pharmacy and Dentistry, University of Science, Techniques and Technologies (USTT), Bamako, Mali. adicko@icermali.org.
Abstract
BACKGROUND: More than 200 million people live in areas of highly seasonal malaria transmission where Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) was recommended in 2012 by WHO. This strategy is now implemented widely and protected more than 19 million children in 2018. It was previously reported that exposure to SMC reduced antibody levels to AMA1, MSP-142 and CSP, but the duration of exposure to SMC up to three 3 years, had no effect on antibody levels to MSP-142 and CSP. METHODS: In 2017, a cross-sectional survey was carried out 1 month after the last dose of SMC had been given to children aged 4-5 years randomly selected from areas where SMC had been given for 2 or 4 years during the malaria transmission season. A total of 461 children were enrolled, 242 children in areas where SMC had been implemented for 4 years and 219 children in areas where SMC had been implemented for 2 years. Antibody extracted from dry blood spots was used to measure IgG levels to the malaria antigens CSP, MSP-142 and AMA1 by ELISA. RESULTS: The prevalence of antibodies to MSP-142 was similar in children who had received SMC for 4 years compared to those who had received SMC for only 2 years (85.1 vs 86.0%, ajusted odd ratio (aOR) = 1.06, 95% confidence intervals (CI 0.62-1.80), p = 0.80). The prevalence of antibodies to AMA-1 and to CSP was not lower in children who received SMC for 4 years compared to those who had received SMC for only 2 years (95.3 vs 88.8%, aOR = 3.16, 95% CI 1.44-6.95, p = 0.004 for AMA-1; and 91.2 vs 81.9%, aOR = 3.14, 95% CI 1.70-5.76, p < 0.001 for CSP). Median antibody levels for anti-MSP-142 IgG were not significatively inferior in children who had received SMC for four rather than 2 years (0.88 (IQR: 0.64-1.15) and 0.95 ((0.68-1.15), respectively), anti-CSP (1.30 (1.00-1.56) and 1.17 (0.87-1.47)), and anti-AMA-1 (1.45 (1.24-1.68) and 1.41 (1.17-1.64)). CONCLUSION: In an area of high seasonal malaria transmission, children who had received SMC for 4 years did not had lower seropositivity or antibody levels to AMA1, MSP-142 and CSP compared to children who had received SMC for only 2 years suggesting that children who have received SMC for 4 years may not be more at risk of malaria after the cessation of SMC than children who have received SMC for a shorter period.
BACKGROUND: More than 200 million people live in areas of highly seasonal malaria transmission where Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) was recommended in 2012 by WHO. This strategy is now implemented widely and protected more than 19 million children in 2018. It was previously reported that exposure to SMC reduced antibody levels to AMA1, MSP-142 and CSP, but the duration of exposure to SMC up to three 3 years, had no effect on antibody levels to MSP-142 and CSP. METHODS: In 2017, a cross-sectional survey was carried out 1 month after the last dose of SMC had been given to children aged 4-5 years randomly selected from areas where SMC had been given for 2 or 4 years during the malaria transmission season. A total of 461 children were enrolled, 242 children in areas where SMC had been implemented for 4 years and 219 children in areas where SMC had been implemented for 2 years. Antibody extracted from dry blood spots was used to measure IgG levels to the malaria antigens CSP, MSP-142 and AMA1 by ELISA. RESULTS: The prevalence of antibodies to MSP-142 was similar in children who had received SMC for 4 years compared to those who had received SMC for only 2 years (85.1 vs 86.0%, ajusted odd ratio (aOR) = 1.06, 95% confidence intervals (CI 0.62-1.80), p = 0.80). The prevalence of antibodies to AMA-1 and to CSP was not lower in children who received SMC for 4 years compared to those who had received SMC for only 2 years (95.3 vs 88.8%, aOR = 3.16, 95% CI 1.44-6.95, p = 0.004 for AMA-1; and 91.2 vs 81.9%, aOR = 3.14, 95% CI 1.70-5.76, p < 0.001 for CSP). Median antibody levels for anti-MSP-142 IgG were not significatively inferior in children who had received SMC for four rather than 2 years (0.88 (IQR: 0.64-1.15) and 0.95 ((0.68-1.15), respectively), anti-CSP (1.30 (1.00-1.56) and 1.17 (0.87-1.47)), and anti-AMA-1 (1.45 (1.24-1.68) and 1.41 (1.17-1.64)). CONCLUSION: In an area of high seasonal malaria transmission, children who had received SMC for 4 years did not had lower seropositivity or antibody levels to AMA1, MSP-142 and CSP compared to children who had received SMC for only 2 years suggesting that children who have received SMC for 4 years may not be more at risk of malaria after the cessation of SMC than children who have received SMC for a shorter period.
Entities:
Keywords:
AMA1; Antibody to MSP-142; CSP; Seasonal malaria chemoprevention; Seropositivity
Authors: Matthew L Plassmeyer; Karine Reiter; Richard L Shimp; Svetlana Kotova; Paul D Smith; Darrell E Hurt; Brent House; Xiaoyan Zou; Yanling Zhang; Merrit Hickman; Onyinyechukwu Uchime; Raul Herrera; Vu Nguyen; Jacqueline Glen; Jacob Lebowitz; Albert J Jin; Louis H Miller; Nicholas J MacDonald; Yimin Wu; David L Narum Journal: J Biol Chem Date: 2009-07-24 Impact factor: 5.157
Authors: Amadou T Konaté; Jean Baptiste Yaro; Amidou Z Ouédraogo; Amidou Diarra; Adama Gansané; Issiaka Soulama; David T Kangoyé; Youssouf Kaboré; Espérance Ouédraogo; Alphonse Ouédraogo; Alfred B Tiono; Issa N Ouédraogo; Daniel Chandramohan; Simon Cousens; Paul J Milligan; Sodiomon B Sirima; Brian Greenwood; Diadier A Diallo Journal: PLoS Med Date: 2011-02-01 Impact factor: 11.069
Authors: Badara Cissé; El Hadj Ba; Cheikh Sokhna; Jean Louis NDiaye; Jules F Gomis; Yankhoba Dial; Catherine Pitt; Mouhamed NDiaye; Matthew Cairns; Ernest Faye; Magatte NDiaye; Aminata Lo; Roger Tine; Sylvain Faye; Babacar Faye; Ousmane Sy; Lansana Konate; Ekoue Kouevijdin; Clare Flach; Ousmane Faye; Jean-Francois Trape; Colin Sutherland; Fatou Ba Fall; Pape M Thior; Oumar K Faye; Brian Greenwood; Oumar Gaye; Paul Milligan Journal: PLoS Med Date: 2016-11-22 Impact factor: 11.069
Authors: Elissa Malkin; Carole A Long; Anthony W Stowers; Lanling Zou; Sanjay Singh; Nicholas J MacDonald; David L Narum; Aaron P Miles; Andrew C Orcutt; Olga Muratova; Samuel E Moretz; Hong Zhou; Ababacar Diouf; Michael Fay; Eveline Tierney; Philip Leese; Siddhartha Mahanty; Louis H Miller; Allan Saul; Laura B Martin Journal: PLoS Clin Trials Date: 2007-04-06
Authors: Amrish Baidjoe; Will Stone; Ivo Ploemen; Shehu Shagari; Lynn Grignard; Victor Osoti; Euniah Makori; Jennifer Stevenson; Simon Kariuki; Colin Sutherland; Robert Sauerwein; Jonathan Cox; Chris Drakeley; Teun Bousema Journal: Malar J Date: 2013-08-02 Impact factor: 2.979
Authors: Catherine E Oldenburg; Abdou Amza; Gretchen Cooley; Boubacar Kadri; Beido Nassirou; Benjamin F Arnold; Philip J Rosenthal; Kieran S O'Brien; Sheila K West; Robin L Bailey; Travis C Porco; Jeremy D Keenan; Thomas M Lietman; Diana L Martin Journal: Malar J Date: 2019-12-03 Impact factor: 2.979